KALV — KALVISTA PHARMACEUTICALS INC
什么是 13F 持仓报告?谁需要申报、何时申报 · 13F 持仓报告看不到什么
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
截至Q2 2026,共 1 家机构在其最新 13F 申报中持有 KALV(KALVISTA PHARMACEUTICALS INC),合计申报市值 $189,对应 7 股。持仓集中度较高:前五大持有人占申报市值的 100.0%,前十大的集中度为 100.0%。
与上一季度相比,1 家新建仓位、191 家清仓退出。13F 数据为季末快照,以上变动反映的是 Q2 2026 末的持仓状态,并非实时交易。
KALVISTA PHARMACEUTICALS INC(KALV)的主要机构持有人包括 Venrock Adviser, LLC、Frazier Life Sciences Management, L.P.、MONTANOVA CAPITAL, LLC,按 13F 申报市值在本页 296 家持有人中排名居前。
本页所有数据均来自美国证监会(SEC)13F 季度申报。13F 申报人需在季度结束后 45 天内披露 10 万美元以上的多头持仓;空头、期权对冲与季度内交易不在其列,因此这些数字反映的是机构持仓的季度快照,而非实时仓位。
机构逐季持仓趋势
| 季度 | 持有机构数 | 股数 | 金额 | 环比净变动 |
|---|---|---|---|---|
| Q2 2026 | 1 | 7 | $189 | — |
| Q1 2026 | 191 | 74.32M | $1.50B | +6.4% |
| Q4 2025 | 164 | 67.77M | $1.09B | +1.0% |
| Q3 2025 | 148 | 62.15M | $756.79M | +4.5% |
| Q2 2025 | 141 | 57.78M | $653.03M | -0.8% |
| Q1 2025 | 134 | 58.21M | $677.06M | -0.4% |
| Q4 2024 | 128 | 58.05M | $491.53M | +9.6% |
| Q3 2024 | 121 | 50.26M | $582.14M | +4.4% |
表内 8 个季度中,机构持股合计减少 100%(Q3 2024 → Q2 2026);单季变动最大的是 Q4 2024(+9.6%)。
更早季度的机构持仓记录(逐季列表): 返回前 25 大机构持仓人
Q1 2026 — 25 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 6.47M | $130.33M | 4.87% | 减持 | |
| 4.96M | $99.87M | 2.57% | 减持 | |
| 4.77M | $95.99M | 2.45% | 持有 | |
| 4.57M | $92.07M | 4.68% | 持有 | |
| 3.80M | $76.41M | 0.00% | 增持 | |
| 2.88M | $57.90M | 7.19% | 增持 | |
| 2.81M | $56.54M | 0.01% | 持有 | |
| 2.81M | $56.54M | 0.01% | 持有 | |
| 2.14M | $43.02M | 0.17% | 减持 | |
| 1.96M | $39.37M | 0.00% | 增持 | |
| 1.91M | $38.49M | 0.02% | 减持 | |
| 1.91M | $38.49M | 0.05% | 增持 | |
| 1.85M | $37.24M | 1.04% | 减持 | |
| 1.84M | $36.95M | 3.81% | 增持 | |
| 1.83M | $36.85M | 0.00% | 新进 | |
| 1.82M | $36.66M | 2.36% | 增持 | |
| 1.51M | $30.39M | 0.12% | 减持 | |
| 1.45M | $29.19M | 3.23% | 增持 | |
| 1.26M | $25.44M | 0.81% | 减持 | |
| 1.24M | $24.88M | 0.49% | 增持 | |
| 1.02M | $20.56M | 5.84% | 增持 | |
| 1.00M | $20.13M | 0.39% | 增持 | |
| 996.24K | $20.06M | 0.00% | 增持 | |
| 897.68K | $18.07M | 4.34% | 增持 | |
| 882.91K | $17.77M | 0.13% | 增持 |
Q4 2025 — 25 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 6.73M | $108.67M | 5.37% | 持有 | |
| 5.04M | $81.39M | 2.19% | 持有 | |
| 4.77M | $77.01M | 1.58% | 持有 | |
| 4.57M | $73.86M | 3.65% | 减持 | |
| 3.75M | $60.63M | 0.00% | 增持 | |
| 2.92M | $47.16M | 0.02% | 增持 | |
| 2.81M | $45.36M | 0.01% | 减持 | |
| 2.81M | $45.36M | 0.01% | 减持 | |
| 2.51M | $40.52M | 0.00% | 持有 | |
| 2.28M | $36.88M | 0.14% | 新进 | |
| 1.92M | $31.03M | 0.12% | 持有 | |
| 1.91M | $30.87M | 0.00% | 增持 | |
| 1.89M | $30.52M | 1.04% | 增持 | |
| 1.81M | $29.25M | 1.95% | 增持 | |
| 1.77M | $28.56M | 2.72% | 增持 | |
| 1.34M | $21.65M | 0.67% | 减持 | |
| 1.27M | $20.56M | 2.50% | 持有 | |
| 1.17M | $18.92M | 0.01% | 增持 | |
| 944.08K | $15.25M | 0.00% | 增持 | |
| 855.46K | $13.82M | 0.67% | 减持 | |
| 835.30K | $13.49M | 0.01% | 减持 | |
| 801.30K | $12.94M | 3.82% | 新进 | |
| 800.00K | $12.92M | 0.16% | 新进 | |
| 700.57K | $11.31M | 0.01% | 增持 | |
| 700.23K | $11.31M | 0.00% | 增持 |
Q3 2025 — 25 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 6.73M | $81.96M | 4.61% | 持有 | |
| 5.04M | $61.41M | 2.36% | 增持 | |
| 5.04M | $61.39M | 1.84% | 增持 | |
| 4.77M | $58.08M | 1.50% | 减持 | |
| 3.18M | $38.70M | 0.01% | 持有 | |
| 3.18M | $38.70M | 0.01% | 持有 | |
| 3.13M | $38.08M | 0.00% | 持有 | |
| 2.50M | $30.46M | 0.00% | 增持 | |
| 2.12M | $25.78M | 0.01% | 增持 | |
| 1.92M | $23.39M | 0.11% | 持有 | |
| 1.80M | $21.93M | 0.01% | 增持 | |
| 1.74M | $21.13M | 2.20% | 增持 | |
| 1.58M | $19.19M | 0.00% | 增持 | |
| 1.36M | $16.61M | 2.35% | 减持 | |
| 1.35M | $16.46M | 0.53% | 增持 | |
| 1.27M | $15.51M | 2.42% | 持有 | |
| 1.16M | $14.14M | 0.01% | 增持 | |
| 928.67K | $11.31M | 0.00% | 减持 | |
| 917.98K | $11.18M | 0.58% | 增持 | |
| 750.00K | $9.13M | 0.41% | 减持 | |
| 704.45K | $8.58M | 0.06% | 新进 | |
| 683.82K | $8.33M | 2.11% | 新进 | |
| 606.17K | $7.38M | 0.55% | 新进 | |
| 596.47K | $7.27M | 0.00% | 增持 | |
| 577.90K | $7.04M | 0.01% | 增持 |
Q2 2025 — 25 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 6.73M | $76.07M | 5.70% | 持有 | |
| 4.96M | $56.02M | 1.73% | 增持 | |
| 4.94M | $55.87M | 2.82% | 持有 | |
| 4.89M | $55.26M | 2.21% | 持有 | |
| 4.67M | $52.85M | 2.78% | 减持 | |
| 3.18M | $35.92M | 0.01% | 持有 | |
| 3.18M | $35.92M | 0.01% | 持有 | |
| 3.13M | $35.38M | 0.00% | 减持 | |
| 2.41M | $27.27M | 0.00% | 增持 | |
| 1.92M | $21.71M | 0.12% | 增持 | |
| 1.83M | $20.71M | 4.28% | 增持 | |
| 1.35M | $15.26M | 0.00% | 增持 | |
| 1.27M | $14.40M | 3.16% | 减持 | |
| 1.04M | $11.74M | 0.43% | 增持 | |
| 945.12K | $10.68M | 0.00% | 增持 | |
| 941.21K | $10.64M | 0.00% | 增持 | |
| 768.97K | $8.69M | 0.53% | 增持 | |
| 679.06K | $7.68M | 0.88% | 减持 | |
| 581.76K | $6.58M | 1.88% | 减持 | |
| 554.96K | $6.27M | 0.01% | 减持 | |
| 430.63K | $4.87M | 0.00% | 增持 | |
| 386.79K | $4.37M | 1.59% | 增持 | |
| 366.97K | $4.15M | 0.00% | 增持 | |
| 352.15K | $3.98M | 0.00% | 减持 | |
| 323.17K | $3.65M | 2.38% | 减持 |
Q1 2025 — 25 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 6.70M | $77.36M | 6.58% | 增持 | |
| 4.94M | $57.03M | 3.15% | 增持 | |
| 4.91M | $56.70M | 2.10% | 持有 | |
| 4.89M | $56.41M | 2.58% | 持有 | |
| 4.75M | $54.83M | 3.92% | 持有 | |
| 3.18M | $36.67M | 0.01% | 减持 | |
| 3.18M | $36.67M | 0.01% | 减持 | |
| 3.15M | $36.37M | 0.00% | 增持 | |
| 2.30M | $26.53M | 0.00% | 增持 | |
| 1.70M | $19.61M | 4.11% | 增持 | |
| 1.62M | $18.67M | 0.12% | 增持 | |
| 1.37M | $15.81M | 3.19% | 持有 | |
| 1.09M | $12.62M | 0.00% | 减持 | |
| 1.01M | $11.71M | 6.20% | 减持 | |
| 915.24K | $10.56M | 0.00% | 增持 | |
| 898.19K | $10.37M | 0.47% | 增持 | |
| 868.01K | $10.36M | 0.01% | 增持 | |
| 753.75K | $8.70M | 1.03% | 新进 | |
| 752.36K | $8.68M | 2.55% | 减持 | |
| 645.99K | $7.46M | 0.00% | 减持 | |
| 608.21K | $7.02M | 0.50% | 增持 | |
| 581.75K | $6.71M | 0.05% | 新进 | |
| 507.70K | $5.86M | 0.00% | 增持 | |
| 450.00K | $5.19M | 0.14% | 新进 | |
| 37.32K | $4.93M | 0.00% | 新进 |
新建仓(Q2 2026)
- IFP Advisors, Inc 7 股 · $189
完全清仓(较上季)
- Venrock Adviser, LLC 卖出 6.47M 股 · $130.33M
- Frazier Life Sciences Management, L.P. 卖出 4.96M 股 · $99.87M
- MONTANOVA CAPITAL, LLC 卖出 4.77M 股 · $95.99M
- TANG CAPITAL MANAGEMENT LLC 卖出 4.57M 股 · $92.07M
- BlackRock Inc 卖出 3.80M 股 · $76.41M
- SILVERARC CAPITAL MANAGEMENT, LLC 卖出 2.88M 股 · $57.90M
- Capital World Investors 卖出 2.81M 股 · $56.54M
- Capital World Investors 卖出 2.81M 股 · $56.54M
- Point72 Asset Management 卖出 2.14M 股 · $43.02M
- STATE STREET CORP 卖出 1.96M 股 · $39.37M
- Millennium Management 卖出 1.91M 股 · $38.49M
- MILLENNIUM MANAGEMENT LLC 卖出 1.91M 股 · $38.49M
基金持仓历史 — 各季度股数(前 20 只基金)
| 基金 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IFP Advisors, Inc | 7 | — | — | 5 | — | 4 | 4 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Venrock Adviser, LLC | — | 6.47M | 6.73M | 6.73M | 6.73M | 6.70M | 6.25M | 6.25M | 6.25M | 6.25M | 4.09M | 2.92M | — | — | — | — | — | — | — | — |
| Frazier Life Sciences Management, L.P. | — | 4.96M | 5.04M | 5.04M | 4.89M | 4.89M | 4.89M | 3.69M | 3.69M | 3.69M | 3.62M | 3.24M | — | — | — | — | — | — | — | — |
| MONTANOVA CAPITAL, LLC | — | 4.77M | 4.77M | 4.77M | 4.96M | 4.91M | 4.91M | 4.21M | 4.19M | 4.19M | 2.68M | 2.42M | — | — | — | — | — | — | — | — |
| TANG CAPITAL MANAGEMENT LLC | — | 4.57M | 4.57M | 5.04M | 4.94M | 4.94M | 4.89M | 4.32M | 4.22M | 4.13M | 3.44M | 3.44M | — | — | — | — | — | — | — | — |
| BlackRock Inc | — | 3.80M | 3.75M | 3.13M | 3.13M | 3.15M | 2.86M | 3.06M | — | — | — | — | — | — | — | — | — | — | — | — |
| SILVERARC CAPITAL MANAGEMENT, LLC | — | 2.88M | 290.60K | 1.36M | 1.83M | 1.70M | 612.17K | 574.56K | 560.88K | 561.18K | 111.73K | 228.93K | — | — | — | — | — | — | — | — |
| Capital World Investors | — | 2.81M | 2.81M | 3.18M | 3.18M | 3.18M | 3.37M | 3.37M | 3.23M | 1.46M | — | — | — | — | — | — | — | — | — | — |
| Capital World Investors | — | 2.81M | 2.81M | 3.18M | 3.18M | 3.18M | 3.37M | 3.37M | 3.23M | 1.46M | — | — | — | — | — | — | — | — | — | — |
| Vestal Point Capital, LP | — | 1.85M | 1.89M | 750.00K | 4.67M | 4.75M | 4.77M | 4.00M | 2.30M | 655.00K | — | — | — | — | — | — | — | — | — | — |
| Millennium Management | — | 1.91M | 2.92M | 2.12M | 430.63K | 198.21K | — | — | — | 19.33K | 50.00K | — | 77.94K | 80.70K | 576.25K | 477.96K | 100.32K | 17.15K | — | 36.72K |
| Point72 Asset Management | — | 2.14M | 2.28M | — | — | — | — | — | — | — | — | — | — | — | — | 57.80K | — | — | — | — |
| TCG Crossover Management, LLC | — | — | — | — | — | — | — | — | — | 1.16M | 3.40M | 3.40M | — | — | — | — | — | — | — | — |
| Vanguard Group | — | — | 2.51M | 2.50M | 2.41M | 2.30M | 2.26M | 2.15M | 1.99M | 1.69M | 1.78M | 1.73M | 1.58M | 1.58M | 1.15M | 1.15M | 1.16M | 1.17M | 1.14M | 1.19M |
| STATE STREET CORP | — | 1.96M | 1.91M | 1.58M | 1.35M | 1.09M | 1.39M | 1.27M | 756.43K | 594.17K | 537.10K | 459.35K | — | — | — | — | — | — | — | — |
| MILLENNIUM MANAGEMENT LLC | — | 1.91M | 23.50K | 20.00K | 90.00K | 198.21K | — | — | — | 19.33K | 50.00K | — | — | — | — | — | — | — | — | — |
| Parkman Healthcare Partners LLC | — | 1.84M | 1.77M | 1.74M | 679.06K | 753.75K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | — | 1.83M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Kynam Capital Management, LP | — | 1.82M | 1.81M | 606.17K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Woodline Partners LP | — | 1.51M | 1.92M | 1.92M | 1.92M | 1.62M | 1.29M | 608.25K | 150.46K | 150.46K | 346.86K | — | — | — | — | — | — | — | — | — |
常见问题
Which funds hold KALV?
As of 2026-Q2, 1 institutional funds reported holding KALV (KALVISTA PHARMACEUTICALS INC) in SEC 13F filings, with a combined reported value of $189.
How many shares of KALV do institutions own?
13F filers reported 7 shares of KALV, worth $189 in aggregate at the end of 2026-Q2.
Is institutional ownership of KALV rising or falling?
No prior-quarter baseline is available for a directional read.
Who are the top institutional holders of KALV?
The largest 13F holders are Venrock Adviser, LLC, Frazier Life Sciences Management, L.P., MONTANOVA CAPITAL, LLC, TANG CAPITAL MANAGEMENT LLC, BlackRock Inc; the top 25 are ranked at the top of this page.
Who are the major shareholders of KALVISTA PHARMACEUTICALS INC?
The major shareholders of KALVISTA PHARMACEUTICALS INC (KALV) by reported 13F value are Venrock Adviser, LLC, Frazier Life Sciences Management, L.P., MONTANOVA CAPITAL, LLC, TANG CAPITAL MANAGEMENT LLC, BlackRock Inc, among 296 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.